Clinical Trial Update: Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT [Phase 2]

View source ↗

Summary

This Phase 2 trial is comparing autologous stem cell transplant followed by anti-BCMA CAR-T therapy versus autologous transplant alone in patients with newly di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-BCMA CAR-T therapy (BCMA-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Xuzhou Medical University | Conditions: Multiple Myeloma, Newly Diagnosed | Phase 2 | Status: NOT_YET_RECRUITING